Kactus and AstraGenomics Enter Strategic Partnership to Accelerate Global Commercialization of Novel Gene Editing Tools
Under the agreement, AstraGenomics has granted Kactus global rights to manufacture and commercialize its innovative gene editing tools. By combining AstraGenomics’ breakthrough platform with Kactus’ industrial-scale capabilities, the collaboration aims to fast-track the development, standardization, and global availability of advanced genome editing solutions for research, therapeutics, and biomanufacturing.
AstraGenomics leverages an integrated “Computational Biology + Lab Automation” discovery platform to develop high-performance gene editing systems, including ultra-compact nucleases and large-fragment gene writing technologies. These tools deliver exceptional precision, safety, and delivery compatibility, enabling transformative applications in cell and gene therapy and beyond.
Kactus specializes in high-quality recombinant proteins for biotherapeutic development. Using its proprietary SAMS™ R&D platform and cGMP-compliant manufacturing facilities, Kactus converts cutting-edge gene editing innovations into reliable, high-activity products. The company has supported numerous global cell and gene therapy programs, helping advance multiple candidates into clinical trials, some pipelines now progressing toward NDA submission. This experience provides a strong foundation for the global launch of the partnership’s products.
Dr. Chengxi Shi, Co-Founder and CEO of AstraGenomics, said:
We’re excited to partner with Kactus Biosystems. This collaboration bridges our foundational innovation with real-world application, accelerating the path from lab to clinic and expanding the impact of our technologies across medicine and biotechnology.
Edmund Wang, Founder and CEO of Kactus Biosystems, stated:
AstraGenomics has developed truly innovative gene editing platforms. We look forward to leveraging our GMP manufacturing excellence, quality systems, and global commercial infrastructure to bring these tools to worldwide, empowering the next wave of genomic innovation.
About AstraGenomics
AstraGenomics is a biotechnology company committed to developing groundbreaking genome editing technologies and therapeutic products. By establishing an innovative intelligent platform that integrates intelligent algorithms with high-throughput automated experimentation, AstraGenomics has developed a diverse portfolio of gene editing tools, including large-fragment gene writing systems and ultra-small nuclease systems. For more detailed information, please visit https://www.astragenomics.com/
About Kactus
Founded in 2018, Kactus is a global provider of high-activity and quality recombinant proteins for biotherapeutic development. The company operates a cGMP production facility and has completed multiple FDA Drug Master File (DMF) submissions. In the gene editing area, Kactus offers a comprehensive nuclease portfolio, including GMP-grade spCas9, cytosine base editor AccuBaseTM, adenine base editor supra-ABE, hfCas12Max® and YolCas12™. With end-to-end capabilities from discovery to clinical supply, Kactus supports innovators worldwide in bringing transformative therapies to patients.
